Drug Trial Radar · NCT04337879
A Study of AL2846 Capsule Combined With Standard Chemotherapy Regimen in Subjects With Advanced Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Jul 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
56
Planned (sponsor's estimate)
Start
Jul 20, 2020
Primary completion
Dec 31, 2020
Study completion Dec 31, 2020
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 8, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to explore the safety, tolerance and efficacy of AL2846 capsules combined with mFOLFOLX6 or FOLFIRI standard chemotherapy regimen in subjects with advanced metastatic colorectal cancer.
Conditions
- Advanced Colorectal Cancer
Interventions
AL2846Drug
AL2846 is a multi-target receptor tyrosine kinase inhibitor, which has obvious selectivity for c-met.
Calcium folateDrug
Calcium folate 400mg/ ㎡ IV on day 1,15 in 28-day cycle
5-FUDrug
5-FU 2800mg/ ㎡ IV on day 1, 2, 15, 16 days in 28-day cycle.
OxaliplatinDrug
Oxaliplatin 85mg/ ㎡ administered intravenously (IV) on day 1, day 15 in 28-day cycle.
IrinotecanDrug
Irinotecan 180mg/㎡ administered intravenously (IV) on day 1,15 in 28-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: up to 12 month
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Hospital of China Medical University
Shengyang, Liaoning, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.